Nuclear imaging in Parkinson's disease: The past, the present, and the future
- PMID: 35313223
- DOI: 10.1016/j.jns.2022.120220
Nuclear imaging in Parkinson's disease: The past, the present, and the future
Abstract
The current review analyzed Parkinson's disease-related (PD) literature published from 1817 to 2021 and specifically concentrated on imaging-related works published from the 1960s to 2021. We analyzed the history of PD-related imaging development, its current condition, and pointed out some understudied aspects to be investigated in the future. The present review is specifically concentrated on nuclear imaging techniques. The available imaging armamentarium for PD investigation is very broad, variable, and diversified and includes structural, diffusion-weighted and diffusion tensor, resting-state, and task-based functional MRI, proton magnetic resonance spectroscopy, transcranial B-mode sonography, single-photon emission CT (SPECT), and positron emission tomography (PET). Specifically, PET is a reliable tool for quantifying nigrostriatal functions, glucose metabolism, amyloid, tau, and α-synuclein molecular imaging, as well as neuroinflammation. Besides 18F-DOPA and 18F-FDG, PET and SPECT use various other radiopharmaceuticals. Also, some studies have demonstrated that myocardial 123I-MIBG scintigraphy can be useful for the early differential diagnosis of patients with PD from other atypical PD. However, in addition to further perfecting of differential diagnosis imaging tools, some aspects of etiology (PD genetics), pathology (the pons and medulla), pathophysiology (neuroinflammation), and early diagnosis of PD remain understudied. The currently available set of neuroimaging tools can provide adequate imaging data for early diagnosis, differential diagnosis, progression assessment, and treatment assessment of PD. To adjust this armamentarium to routine clinical needs, there is an urgent need for the generally accepted protocol for PD-related imaging investigations. Closer cooperation and data exchange between radiologists and pathologists are desirable.
Keywords: (18)F-DOPA; MRI; Neuroimaging; Parkinson's disease; Positron emission tomography.
Copyright © 2022 Elsevier B.V. All rights reserved.
Similar articles
-
Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.Front Neurol. 2020 Oct 15;11:572976. doi: 10.3389/fneur.2020.572976. eCollection 2020. Front Neurol. 2020. PMID: 33178113 Free PMC article. Review.
-
Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.Mol Med. 2021 Sep 16;27(1):111. doi: 10.1186/s10020-021-00327-x. Mol Med. 2021. PMID: 34530732 Free PMC article. Review.
-
Neuroimaging of Parkinson's disease: Expanding views.Neurosci Biobehav Rev. 2015 Dec;59:16-52. doi: 10.1016/j.neubiorev.2015.09.007. Epub 2015 Sep 26. Neurosci Biobehav Rev. 2015. PMID: 26409344 Free PMC article. Review.
-
The role of neuroimaging in Parkinson's disease.J Neurochem. 2021 Nov;159(4):660-689. doi: 10.1111/jnc.15516. Epub 2021 Oct 3. J Neurochem. 2021. PMID: 34532856 Free PMC article. Review.
-
Neuroimaging in Parkinsonian Disorders.Neurol India. 2018 Mar-Apr;66(Supplement):S68-S78. doi: 10.4103/0028-3886.226460. Neurol India. 2018. PMID: 29503329 Review.
Cited by
-
Precision Imaging in Neurodegeneration: The Superiority of Diffusion Tensor Imaging Over Conventional MRI in Differentiating Parkinson's Disease From Atypical Parkinsonian Syndromes.Cureus. 2024 Sep 8;16(9):e68933. doi: 10.7759/cureus.68933. eCollection 2024 Sep. Cureus. 2024. PMID: 39381485 Free PMC article.
-
Attention-enhanced dilated convolution for Parkinson's disease detection using transcranial sonography.Biomed Eng Online. 2024 Jul 31;23(1):76. doi: 10.1186/s12938-024-01265-5. Biomed Eng Online. 2024. PMID: 39085884 Free PMC article.
-
Imaging advances to detect non-motor prodromal markers of Parkinson's disease and explore therapeutic translation opportunities.NPJ Parkinsons Dis. 2025 Jun 18;11(1):174. doi: 10.1038/s41531-025-01004-0. NPJ Parkinsons Dis. 2025. PMID: 40533452 Free PMC article. Review.
-
Role of 6-Fluoro-18F-l-3,4-DOPA MR-PET in Clinical Workup in Movement Disorders Cases: An Exploratory Study in a Tertiary Care Neuropsychiatric Setup.Indian J Nucl Med. 2025 Jan-Feb;40(1):10-15. doi: 10.4103/ijnm.ijnm_151_23. Epub 2025 May 16. Indian J Nucl Med. 2025. PMID: 40453438 Free PMC article.
-
Co-administration of Nanowired DL-3-n-Butylphthalide (DL-NBP) Together with Mesenchymal Stem Cells, Monoclonal Antibodies to Alpha Synuclein and TDP-43 (TAR DNA-Binding Protein 43) Enhance Superior Neuroprotection in Parkinson's Disease Following Concussive Head Injury.Adv Neurobiol. 2023;32:97-138. doi: 10.1007/978-3-031-32997-5_3. Adv Neurobiol. 2023. PMID: 37480460 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous